---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-015762"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:07:35.815267+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech secures Hong Kong patent for liposomal Annamycin through 2040

## Summary
- Hong Kong patent No. 40073244 covers proprietary reconstitution method of liposomal Annamycin, expiring June 25, 2040.
- Invention jointly owned with The University of Texas System; extends IP protection across four continents.
- Company expects first Phase 3 clinical data release for Annamycin later this quarter.
- Existing granted/allowed patents include US, Australia, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, Taiwan.

## SEC filing metadata
- accession: 0001437749-26-015762
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926015762/0001437749-26-015762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926015762/mbrx20260507_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-015762
- JSON: https://secwatch.observer/filing/0001437749-26-015762.json
- Plain text: https://secwatch.observer/filing/0001437749-26-015762.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.